{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-005787","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2022-04-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.050766+00:00","generated_at":"2026-06-26T06:34:19.332085+00:00","sec_items":["2.05","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Finch Therapeutics cuts 20% of workforce (37 FTE); focuses on CDI and ASD after FDA clinical hold","bullets":["Reduction of 37 full-time employees (~20% of workforce) approved by board on April 14, 2022.","Estimates ~$1.1M in one-time severance and related costs, recorded in Q2 2022.","Restructuring follows FDA clinical hold on CP101 (SARS-CoV-2 donor screening) and pause of chronic hepatitis B program.","Company has submitted complete response to FDA on clinical hold and awaits feedback.","Prioritizing recurrent C. difficile infection (CDI) and autism spectrum disorder (ASD) programs; Takeda-partnered IBD work continues."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-005787","json":"https://secwatch.observer/filing/0000950170-22-005787.json","markdown":"https://secwatch.observer/filing/0000950170-22-005787.md","text":"https://secwatch.observer/filing/0000950170-22-005787.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022005787/0000950170-22-005787-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022005787/fnch-20220414.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T06:34:19.332085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}